Marksans Pharma Limited

Marksans Pharma Limited, established in 1992, is a prominent Indian pharmaceutical company specializing in the research, manufacturing, marketing, and sale of finished pharmaceutical formulations. Headquartered in Mumbai, Maharashtra, the company has expanded its global footprint, operating in over 50 countries and offering a diverse portfolio of over 300 products across 15 therapeutic areas.

The company's authorized share capital stands at ₹690 million, with a paid-up capital of ₹453.16 million. Marksans Pharma Limited is listed on the Bombay Stock Exchange (BSE) under the code 524404 and on the National Stock Exchange (NSE) under the symbol MARKSANS.

Marksans Pharma Limited operates state-of-the-art manufacturing facilities in North Goa, India; Verna, India; Farmingdale, USA; and Southport, UK. These facilities are approved by regulatory agencies such as the US FDA, UK MHRA, and Australian TGA, ensuring compliance with international quality standards.

The leadership team at Marksans Pharma Limited includes:

• Mark B. Saldanha: Non-Independent Executive Chairman and Managing Director.

• Jitendra M. Sharma: Group Chief Financial Officer.

• Harshavardhan Panigrahi: Company Secretary, Manager of Legal and Compliance Officer.

• Sandra Saldanha: Whole-Time Executive Non-Independent Director.

• Varddhman Vikramaditya Jain: Whole-Time Executive Non-Independent Director.

Marksans Pharma Limited has a significant presence in regulated markets, including the United States, Europe, the United Kingdom, Australia, and New Zealand. The company's manufacturing facilities in the USA and UK have received approvals from the US FDA and UK MHRA, respectively, facilitating access to these markets.

In August 2025, Marksans Pharma Inc., a wholly owned subsidiary, received US FDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC), demonstrating the company's commitment to expanding its product offerings in the US market.

Marksans Pharma Limited has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards and regulatory approvals has enabled it to penetrate these markets effectively.

The company's geographic strategy focuses on diversification, reducing concentration risk by operating in over 50 countries. This approach allows Marksans Pharma Limited to mitigate market-specific risks and capitalize on growth opportunities across different regions.

Marksans Pharma Limited's wholly owned subsidiary, Time-Cap Laboratories, Inc., received an Establishment Inspection Report (EIR) from the US FDA for an audit conducted in October 2023, with no 483 observations issued during the audit.

In June 2020, the company voluntarily recalled Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, due to the detection of N-Nitrosodimethylamine (NDMA).

Marksans Pharma Limited's manufacturing facilities have been approved by the World Health Organization (WHO) and hold European Union Good Manufacturing Practice (EU GMP) certificates, ensuring compliance with international quality standards.

Marksans Pharma Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its operations within India and for export purposes.

In June 2020, Marksans Pharma Limited voluntarily recalled Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, due to the detection of N-Nitrosodimethylamine (NDMA).

In October 2020, the company expanded the recall to include Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg, due to the detection of NDMA.

Marksans Pharma Limited faces competition from other pharmaceutical companies in overlapping therapeutic categories, including pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, and others. A detailed market share comparison and head-to-head analysis would require access to proprietary market research data.

Marksans Pharma Limited's key differentiators include its extensive product portfolio, adherence to international quality standards, and a strong global presence. The company's manufacturing facilities are approved by regulatory agencies such as the US FDA, UK MHRA, and Australian TGA, ensuring compliance with stringent quality norms.

Marksans Pharma Limited's current strategic direction focuses on expanding its presence in regulated markets, enhancing its product portfolio, and strengthening its global footprint. The company's recent US FDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC), reflects its commitment to growth in the US market.

Marksans Pharma Limited has a track record of consistent export performance, with a total export value of $125.0 million USD and 4,477 shipments across 22 products in 11 therapeutic categories. The company's top five products—Ibuprofen, Amino, Gabapentin, Acetaminophen, and Loratadine—account for 73.7% of its export portfolio, indicating a focused approach in its product offerings.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirmed through the US FDA's Establishment Inspection Report (EIR) issued to Time-Cap Laboratories, Inc. in October 2023.

• WHO-GMP Certification: Marksans Pharma Limited's manufacturing facilities are approved by the World Health Organization (WHO).

• EU GMP Certification: The company's manufacturing facilities hold European Union Good Manufacturing Practice (EU GMP) certificates.

• ISO Certification: Importers should request ISO certification details from Marksans Pharma Limited to verify compliance with international quality standards.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm FDA, WHO-GMP, and EU GMP certifications.

• Assess Product Portfolio: Evaluate the range and quality of products offered.

• Review Financial Stability: Analyze financial statements to assess the company's financial health.

• Check Compliance History: Investigate any past recalls or regulatory actions.

• Evaluate Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain operations.

Red flags to watch for include:

• Lack of Regulatory Approvals: Absence of necessary certifications may indicate potential quality issues.

• Frequent Recalls: A history of product recalls could signal quality control problems.

• Financial Instability: Unstable financial performance may affect the company's ability to fulfill orders.

Recommended pre-order checks:

• Request Documentation: Obtain copies of all relevant certifications and approvals.

• Conduct Site Visits: If possible, visit manufacturing facilities to assess compliance with quality standards.

• Engage Third-Party Auditors: Consider hiring independent auditors to evaluate the company's operations and compliance.